Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics**Supported in part by Sandoz Pharma Ltd., CH-4002, Basle, Switzerland.
- Resource Type
- Article
- Authors
- Espinós, Juan J.; Rodríguez-Espinosa, José; Webb, Susan M.; Calaf-Alsina, Joaquin
- Source
- Fertility and Sterility; November 1994, Vol. 62 Issue: 5 p926-931, 6p
- Subject
- Language
- ISSN
- 00150282; 15565653
To study the efficacy of long-acting repeatable bromocriptine in supressing abnormal PRL secretion in microprolactinoma patients. To assess the incidence and nature of side effects induced by the product.